

Approved for use through 07/31/2006. OMB 0651-0034
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Application Number	10/550,518
Filing Date	September 23, 2005
First Named Inventor	BACHMANN, Martin F.
Art Unit	1633
Examiner Name	LI, Qian Janice
Attorney Docket Number	1700.0630000/BJD/WBC

Sheet	1	of	1
-------	---	----	---

Examiner Signature	/Q. Janice Li/ (11/20/2008)	Date Considered	
--------------------	-----------------------------	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard S1.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-FTC-9199 and select option 2.

Rev. 11-03-03 syb

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qjl/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/550,518
		Filing Date	September 23, 2005
		First Named Inventor	BACHMANN, Martin F.
		Art Unit	1633
		Examiner Name	LI, Qian Janice
Sheet 1 of 2	Attorney Docket Number	1700.0630000/BJD/WBC	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL179	Ashcroft, <i>et al.</i> (2003) Immunity 19(6):849-61 -- Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Cell Press.	
	NPL180	Axblom, <i>et al.</i> (1998) Virology 249(NA):80-8 -- Structure of Phage fr capsids with a Deletion in the FG loop: Implications for Viral Assembly. Academic Press.	
	NPL181	Azuma (1992) Vaccine 10(14):1000-6 -- Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Elsevier Science.	
	NPL182	Bird (1987) TIG 3(12):342-347 -- CpG islands as gene markers in the vertebrate nucleus. Elsevier Trends Journals.	
	NPL183	Branda, <i>et al.</i> (1993) Biochem Pharmacol 45(10):2037-43 -- Immune stimulation by an antisense oligomer complementary to the <i>rev</i> gene of HIV-1. Elsevier Science.	
	NPL184	Francois, <i>et al.</i> (1988) Clin Immunol Immunopathol 48(3):297-306 -- Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Academic Press.	
	NPL185	Gilkeson, <i>et al.</i> (1989) Clin Immunol Immunopathol 51(3):362-71 -- The antibody response of normal mice to immunization with single-stranded DNA of various species origin. Academic Press.	
	NPL186	Holt (1994) Lancet 344(8920):456-8 -- A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet Publishing Group.	
	NPL187	Kataoka, <i>et al.</i> (1988) Jpn J Cancer Res 79(7):817-20 -- A synthetic adjuvant effective in inducing antitumor immunity. Japanese Cancer Association.	
	NPL188	Lotz, <i>et al.</i> (1987) J Rheumatol 14(1):42-5 -- Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. Journal Of Rheumatology Publishing Co.	
	NPL189	McIntyre, <i>et al.</i> (1993) Antisense Res Dev 3(4):309-22 -- A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. Mary Ann Liebert.	

Examiner Signature	/Q. Janice Li/ (11/20/2008)	Date Considered	
--------------------	-----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qj//

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/530,518
		Filing Date	September 23, 2005
		First Named Inventor	BACHMANN, Martin F.
		Art Unit	1633
Examiner Name	LI, Qian Janice		
Attorney Docket Number	1700.0630000/BJD/WBC		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL190	Merritt, <i>et al.</i> (1965) J Immunol 94(3):416-22 -- Studies on the Adjuvant action of bacterial endotoxins on antibody formation. VI. Enhancement of Antibody formation by nucleic acids. American Association of Immunologists.	
	NPL191	Messina, <i>et al.</i> (1991) J Immunol 147(6):1759-64 -- Stimulation of <i>in vitro</i> murine lymphocyte proliferation by bacterial DNA. American Association of Immunologists.	
	NPL192	Messina, <i>et al.</i> (1993) Cell Immunol 147(1):148-57 -- The influence of DNA structure on the <i>in vitro</i> stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Academic Press.	
	NPL193	Mojcik, <i>et al.</i> (1993) Clin Immunol Immunopathol 67(2):130-6 -- Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF <i>env</i> causes immune effects <i>in vivo</i> in a sequence-specific manner. Academic Press.	
	NPL194	Nohria, <i>et al.</i> (1994) Biotherapy 7(3-4):261-9 -- Cytokines as potential vaccine adjuvants. Kluwer Academic Publishers.	
	NPL195	Peabody (1997) Arch Biochem Biophys 347(1):85-92 -- Subunit fusion confers tolerance to peptide insertions in a virus coat protein. Academic Press.	
	NPL196	Pisetsky, <i>et al.</i> (1993) Mol Biol Rep 18(3):217-21 -- Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Reidel.	
	NPL197	Saiki, <i>et al.</i> (1988) Vaccine 6(3):238-44 -- Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues. Elsevier Science.	
	NPL198	Stonehouse, <i>et al.</i> (1993) FEBS Lett 334(3):355-9 -- Effects of amino acid substitution on the thermal stability of MS2 capsids lacking genomic RNA. Elsevier Science.	

Examiner Signature	/Q. Janice LI/ (11/20/2008)	Date Considered	
--------------------	-----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.